MedTrace Logo

An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

NCT03977792 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2020-09-07

No results posted yet for this study

Summary

BOR15001L7 is a natural product. The primary objective of this study is to demonstrate its non-inferiority to docosanol 10% based on the healing time of cold sores in patients with recurrent herpes labialis.

Conditions

  • Recurrent Herpes Labialis

Interventions

DRUG

BOR15001L7

BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.

DRUG

Docosanol Cream 10%

Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.

Sponsors & Collaborators

  • Ecogene 21

    collaborator OTHER

  • Laboratoire Boreaderme Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-07-31
Completion
2022-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03977792 on ClinicalTrials.gov